Vicore Pharma’s Board of Directors has resolved on a directed share issue of around SEK 160 million to finance the continued development of the drug development programs VP01 and VP02

NOT FOR DISTRIBUTION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UK, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH MEASURES WOULD BE IN VIOLATION OF APPLICABLE REGULATIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN VICORE PHARMA HOLDING IN ANY JURISDICTION.Mölndal, 30 November 2018 – The Board of Directors of Vicore Pharma Holding AB (publ) (”Vicore Pharma”, or the ”Company”) has resolved, subject to the approval by an Extraordinary General Meeting (the “EGM”),